Expert Opinion on Investigational Drugs, Volume 32, Issue 5 (2023)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 32, Issue 5 (2023)

See all volumes and issues
Vol 33, 2024 Volume 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Drug Evaluation

Article
Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus
Sung Kyung Cho, Thomas Vazquez & Victoria P. Werth
Pages: 345-353
Published online: 15 May 2023
AbstractforLitifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus | Full Text | References | PDF (990.1 KB) | EPUB
  • 446 Views
  • 0 CrossRef citations
  • 0Altmetric

Key Paper Evaluation

Article
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Sheila A Doggrell
Pages: 355-359
Published online: 24 Apr 2023
AbstractforIs retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? | Full Text | References | PDF (191.5 KB) | EPUB
  • 1348 Views
  • 2 CrossRef citations
  • 0Altmetric

Special Report

Article
Recent developments for new investigational JAK inhibitors in psoriatic arthritis
Francesco Caso, Luisa Costa, Paola Triggianese, Francesco Maione, Nicoletta Bertolini, Maria Vastarella, Maria Sole Chimenti & Marco Tasso
Pages: 361-371
Published online: 03 May 2023
AbstractforRecent developments for new investigational JAK inhibitors in psoriatic arthritis | Full Text | References | PDF (348 KB) | EPUB
  • 446 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
Investigational anti IL-13 asthma treatments: a 2023 update
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Paola Rogliani & Mario Cazzola
Pages: 373-386
Published online: 18 May 2023
AbstractforInvestigational anti IL-13 asthma treatments: a 2023 update | Full Text | References | PDF (2.3 MB) | EPUB
  • 389 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma
Jing Wang, Christian Karime, Umair Majeed, Jason S. Starr, Mitesh J. Borad & Hani M. Babiker
Pages: 387-399
Published online: 24 Apr 2023
AbstractforTargeting leukemia inhibitory factor in pancreatic adenocarcinoma | Full Text | References | PDF (2.8 MB) | EPUB
  • 228 Views
  • 0 CrossRef citations
  • 0Altmetric

Systematic Review

Systematic Review
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Gia Han Le, Emily S. Gillissie, Taeho Greg Rhee, Bing Cao, Yazen Alnefeesi, Ziji Guo, Joshua D. Di Vincenzo, Muhammad Youshay Jawad, Andrew M. March, Ranuk Ramachandra, Leanna M.W. Lui & Roger S. McIntyre
Pages: 401-415
Published online: 01 May 2023
AbstractforEfficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials | Full Text | References | PDF (1.9 MB) | EPUB | Supplemental
  • 430 Views
  • 1 CrossRef citations
  • 0Altmetric

Original Research

Article
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults
Christopher Wynne, Paul Hamilton, Kristi McLendon, Heimo Stroissnig, Matthew Smith, Paul Duijzings, Ruth Ruffieux, Hendrik Otto, Abid Sattar, Halimu N. Haliduola, Steffen Leutz & Fausto Berti
Pages: 417-427
Published online: 23 May 2023
AbstractforA randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults | Full Text | References | PDF (1 MB) | EPUB | Supplemental
  • 1604 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, Min Kyu Park, Jun Gi Hwang, Min-Gul Kim, Hyewon Chung, JongLyul Ghim, Jae-Yong Chung, Josef S. Smolen, Gerd R. Burmester, SungHyun Kim, YunJu Bae, DaBee Jeon, JaeKyoung Yoo, GoEun Yang, JiHun Bae & Edward Keystone
Pages: 429-439
Published online: 26 May 2023
AbstractforPharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study | Full Text | References | PDF (330.3 KB) | EPUB | Supplemental
  • 1874 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach
Yueting Chen, Yang Yang, Shansen Xu, Chenyu Wang, Pan Shu, Xiaoyu Zhang, Qin Huang, Jin Sook Kim & Zheng Jiao
Pages: 441-450
Published online: 15 May 2023
AbstractforModel Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach | Full Text | References | PDF (4.6 MB) | EPUB | Supplemental
  • 138 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy
Ava Aghakhani et al.
Review Article | Published online: 30 May 2024
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus
Eric F. Morand et al.
Plain Language Summary of Publication | Published online: 29 May 2024
Open Access
Inflammation and Huntington’s disease – a neglected therapeutic target?
Sophie E. Field et al.
Review Article | Published online: 29 May 2024
Open Access
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration
Shogo Hashimoto et al.
Review Article | Published online: 29 May 2024
View all latest articles